Emergence of Vitiligo during Treatment with Risankizumab-Rzaa for Plaque Psoriasis: A Case Report [PDF]
Case Reports in DermatologyIntroduction: Risankizumab-rzaa (Skyrizi) is a humanized monoclonal antibody (IgG1) approved for the treatment of severe plaque psoriasis.
Kevin V. Thomas +2 more
doaj +2 more sources
Comparative Effectiveness of Bimekizumab and Risankizumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison [PDF]
Rheumatology and TherapyIntroduction The relative efficacy of bimekizumab and risankizumab in patients with PsA who were biologic disease-modifying anti-rheumatic drug naïve (bDMARD naïve) or with previous inadequate response or intolerance to tumor necrosis factor inhibitors ...
Philip J. Mease +8 more
doaj +2 more sources
Shorter Crohn’s Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies [PDF]
Gastro Hep AdvancesBackground and Aims: Early biologic therapy treatment has demonstrated better outcomes in Crohn’s disease (CD). We evaluated the impact of CD duration in patients with moderately to severely active CD treated with risankizumab therapy. Methods: This post
Laurent Peyrin-Biroulet +12 more
doaj +3 more sources
Real-World Efficacy of IL-23 Inhibitors in Psoriasis Affecting High-Impact Areas: Indirect Comparison of Tildrakizumab 200 mg, Risankizumab, and Guselkumab—IL PSO (Italian Landscape Psoriasis) [PDF]
Dermatology and TherapyIntroduction Psoriasis involving special or high-impact areas (scalp, nails, palms/soles, genitalia) is associated with a disproportionate functional and psychological burden that is often underestimated by conventional severity scores and remains ...
Emanuele Trovato +33 more
doaj +2 more sources
Single-cell RNA sequencing and in vitro validation reveal risankizumab induces anti-inflammatory macrophage polarization in psoriasis [PDF]
European Journal of Medical ResearchBackground Risankizumab was an approved novel drug by Japan for psoriasis, we aimed to explore its underlying therapeutic mechanism through the single-cell RNA sequencing (scRNA-seq) technology.
Yuan Yuan +7 more
doaj +2 more sources
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials [PDF]
Dermatology and TherapyIntroduction The presence (vs absence) of enthesitis/dactylitis is associated with greater psoriatic arthritis (PsA) activity and reduced health-related quality of life. Risankizumab, an interleukin 23 antagonist, demonstrated superior treatment efficacy
Shawn G. Kwatra +8 more
doaj +2 more sources
Efficacy and safety of risankizumab in moderate-to-severe Crohn’s disease: a systematic review and meta-analysis [PDF]
Therapeutic Advances in GastroenterologyBackground: Crohn’s disease (CD) is a chronic inflammatory disorder with limited therapeutic options for treatment-refractory patients. This meta-analysis evaluates the efficacy and safety of risankizumab (IL-23 p19 inhibitor) in moderate-to-severe CD ...
Hafsa Nasim +9 more
doaj +2 more sources
Risankizumab in severe asthma - A phase 2a, placebo-controlled trial [PDF]
, 2021 Background: Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear ...
Brightling, Christopher
core +6 more sources
Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience [PDF]
, 2023 Background: Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar ...
Gaia Moretta +9 more
core +1 more source
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn’s Disease in a Randomized Phase 3 Trial [PDF]
, 2023 Background and Aims Durable clinical remission, endoscopic healing, and biomarker normalization are key treatment goals for Crohn’s disease. The selective anti-interleukin-23 p19 inhibitor risankizumab demonstrated efficacy and safety in moderately to ...
Alexandra Song +39 more
core +1 more source